JP2008538812A - 方法 - Google Patents

方法 Download PDF

Info

Publication number
JP2008538812A
JP2008538812A JP2008506405A JP2008506405A JP2008538812A JP 2008538812 A JP2008538812 A JP 2008538812A JP 2008506405 A JP2008506405 A JP 2008506405A JP 2008506405 A JP2008506405 A JP 2008506405A JP 2008538812 A JP2008538812 A JP 2008538812A
Authority
JP
Japan
Prior art keywords
sdldl
bound
particles
amount
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008506405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538812A5 (https=
Inventor
カメジョ，ゲルマン
ダヴィッドソン，ピア
ハルゼ，ヨハネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2008538812A publication Critical patent/JP2008538812A/ja
Publication of JP2008538812A5 publication Critical patent/JP2008538812A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2008506405A 2005-04-11 2006-04-10 方法 Withdrawn JP2008538812A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500808 2005-04-11
PCT/SE2006/000425 WO2006110082A1 (en) 2005-04-11 2006-04-10 A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes.

Publications (2)

Publication Number Publication Date
JP2008538812A true JP2008538812A (ja) 2008-11-06
JP2008538812A5 JP2008538812A5 (https=) 2009-04-09

Family

ID=37087285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506405A Withdrawn JP2008538812A (ja) 2005-04-11 2006-04-10 方法

Country Status (5)

Country Link
US (1) US20090280501A1 (https=)
EP (1) EP1872138A1 (https=)
JP (1) JP2008538812A (https=)
CN (1) CN101166981A (https=)
WO (1) WO2006110082A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010190804A (ja) * 2009-02-19 2010-09-02 Biomarker Science:Kk 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
JP2012533066A (ja) * 2009-07-07 2012-12-20 イントリンジック バイオプローブズ，インコーポレイテッド 糖尿病前症及び２型糖尿病におけるアポリポタンパク質ｃｉｉｉ
JP2013541706A (ja) * 2010-09-21 2013-11-14 プロテオミクス インターナショナル プロプライエタリー リミテッド 糖尿病前症、糖尿病、および糖尿病関連症状に関連するバイオマーカー

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2517572C (en) * 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP2015077B1 (en) * 2006-05-01 2012-10-31 DENKA SEIKEN Co., Ltd. Method for detection of familial combined hyperlipidemia
JP2008116248A (ja) * 2006-11-01 2008-05-22 Yoshikimi Kikuchi 子宮体癌の検出方法
AT505727B1 (de) * 2007-09-04 2009-06-15 Univ Innsbruck Verfahren zur diagnose des metabolischen syndroms
KR20110086074A (ko) * 2008-10-20 2011-07-27 리포사이언스, 인크. 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램
CN102565416A (zh) * 2010-12-27 2012-07-11 中国科学院上海生命科学研究院 载脂蛋白a1作为糖尿病标志物的应用
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
KR101355394B1 (ko) 2011-08-03 2014-01-29 서울대학교산학협력단 임신성 당뇨 조기 진단 정보를 제공하는 방법 및 임신성 당뇨 조기 진단 정보를 제공하는데 사용되는 임신성 당뇨 모니터링, 진단 및 스크리닝용 키트
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CN103376323A (zh) * 2012-04-25 2013-10-30 中国科学院上海生命科学研究院 载脂蛋白c-iii作为肥胖型糖尿病标志物的应用
CN107884467A (zh) * 2017-10-31 2018-04-06 北京毅新博创生物科技有限公司 改善质谱检测糖基结晶的方法及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
US20040137521A1 (en) * 2001-06-05 2004-07-15 Jamila Najib-Fruchart Method for apo clll measurement in apo b and non apo b containing particles
JP4593026B2 (ja) * 2001-07-18 2010-12-08 栄研化学株式会社 ＳｍａｌｌｄｅｎｓｅＬＤＬの測定方法
WO2003029829A1 (en) * 2001-10-01 2003-04-10 The Texas A & M University System Lipoprotein fingerprinting method
ATE505731T1 (de) * 2002-12-06 2011-04-15 Denka Seiken Kk Verfahren zur quantifizierung von kleinen lipoproteinen mit geringer dichte

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010190804A (ja) * 2009-02-19 2010-09-02 Biomarker Science:Kk 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
JP2012533066A (ja) * 2009-07-07 2012-12-20 イントリンジック バイオプローブズ，インコーポレイテッド 糖尿病前症及び２型糖尿病におけるアポリポタンパク質ｃｉｉｉ
JP2013541706A (ja) * 2010-09-21 2013-11-14 プロテオミクス インターナショナル プロプライエタリー リミテッド 糖尿病前症、糖尿病、および糖尿病関連症状に関連するバイオマーカー

Also Published As

Publication number Publication date
US20090280501A1 (en) 2009-11-12
WO2006110082A1 (en) 2006-10-19
CN101166981A (zh) 2008-04-23
EP1872138A1 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
US8420337B2 (en) Lipoprotein-associated markers for cardiovascular disease
Diniz Pereira et al. Alzheimer’s disease and type 2 diabetes mellitus: A systematic review of proteomic studies
Begue et al. Altered high-density lipoprotein composition and functions during severe COVID-19
JP7008268B2 (ja) 脳内のアミロイドβペプチド蓄積状態を評価するサロゲート・バイオマーカー及びその分析方法
US8241861B1 (en) Methods and compositions for diagnosis or prognosis of cardiovascular disease
Vaisar Proteomics investigations of HDL: challenges and promise
Sihlbom et al. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer’s disease patients and healthy individuals
Mokou et al. Proteomics in cardiovascular disease: recent progress and clinical implication and implementation
CN110088627B (zh) 生物标志物
JP2008538812A (ja) 方法
Zhang et al. Quantitative proteomic analysis of serum proteins in patients with Parkinson’s disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry
Thongboonkerd et al. Urinary proteomics and biomarker discovery for glomerular diseases
Wang et al. Tetranectin and apolipoprotein A‐I in cerebrospinal fluid as potential biomarkers for Parkinson’s disease
Ku et al. Discovery of plasma biomarkers for predicting the severity of coronary artery atherosclerosis by quantitative proteomics
TWI822802B (zh) 腎病變蛋白生物標記及其應用
JP7735371B2 (ja) アルツハイマー病の診断と予後判定におけるマーカーとしてのｐ５３ペプチド
WO2010032458A1 (ja) 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法
US20110263450A1 (en) Alzheimer's disease biomarkers
US20130073308A1 (en) Methods of Detecting a Fragment of Neurosecretory Protein VGF for Diagnosing Alzheimer's Disease
JP2008537143A (ja) アルツハイマー病のためのバイオマーカーであるサポシンｄ及びｆａｍ３ｃ
JP5468218B2 (ja) 皮膚老化改善・進行遅延効果の評価方法、物質のスクリーニング方法、並びに、マーカーとしての使用
EP2059818A2 (en) Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes
US20110008903A1 (en) Methods and kits for determining the occurrence of a liver disease in a subject
WO2015105883A1 (en) Apolipoprotein c biomarkers and methods for cholesterol efflux and cardiovascular health
JP2013542453A (ja) 疾患のバイオマーカーとしてのアルブミン結合タンパク質／ペプチド複合体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090219

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100107